Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
Status:
Withdrawn
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
This study has 2 parts: a Dose Escalation Part and a Dose Expansion Part.
The goal of the Dose Escalation Part of this clinical research study is to find the highest
tolerable dose of nivolumab in combination with ipilimumab and the standard of care
(lenalidomide and dexamethasone) that can be given to patients with multiple myeloma (MM).
The goal of the Dose Expansion Part of this clinical research study is to continue to study
the safety of the highest tolerable dose found in Phase 1 of the study.